Alta Life Sciences

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system aimed at the early detection of sepsis. The company focuses on rapidly identifying pathogens and providing antibiogram results within hours. Utilizing artificial intelligence, DeepUll's system not only detects the causative infectious agents but also assesses the patient's immunological and functional status, allowing for predictive insights into the potential onset and progression of sepsis. This capability enables healthcare professionals to deliver timely clinical responses, even before symptoms manifest, ultimately improving patient outcomes and reducing the unnecessary use of antimicrobials.

Peptomyc is a biotechnology company dedicated to developing innovative therapeutics that utilize cell-penetrating peptides to target the Myc oncoprotein, a critical factor in cancer cell survival. Founded in December 2014, the company is rooted in over two decades of research by Dr. Soucek on Omomyc, recognized as the most effective direct Myc inhibitor. With cancer incidence surpassing 14 million cases annually and projected to rise significantly, conventional treatments often fail due to resistance. Peptomyc's approach seeks to inhibit Myc, which is deregulated in most human cancers and plays an essential role in tumor evolution. This strategic focus on Myc represents a promising avenue in cancer therapy, particularly for challenging cases such as lung, breast, and brain tumors, offering the potential to enhance patient survival rates where existing therapies may fall short.

Mediktor is a developer of an advanced pre-diagnosis tool that utilizes artificial intelligence and natural language recognition to facilitate accurate symptom checking, triage, and decision-making support. The system is clinically validated and aims to transform healthcare by reducing access barriers for patients. It allows individuals to make informed decisions based on their initial symptoms while enabling healthcare providers to efficiently manage demand and optimize resources. Mediktor's technology connects patients with medical professionals within health insurance networks, assisting hospitals and health systems in making safe, rapid, and cost-effective healthcare decisions.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Inbiomotion is a biotechnology company founded in 2010 by Dr. Roger Gomis, originating as a spin-off from IRB Barcelona and ICREA research institutions. The company specializes in developing and commercializing a biomarker that predicts metastasis in early-stage breast cancer patients. Its unique diagnostic assay leverages a highly selective single-gene biomarker, which has been shown to identify patients who may benefit from bisphosphonate adjuvant treatment, subsequently improving their overall survival and invasive disease-free survival rates. By utilizing this biomarker, Inbiomotion aims to evaluate the risk of metastases relapse from primary tumors, thereby facilitating a more personalized approach to treatment and advancing the clinical standard of care for breast cancer patients.

Peptomyc is a biotechnology company dedicated to developing innovative therapeutics that utilize cell-penetrating peptides to target the Myc oncoprotein, a critical factor in cancer cell survival. Founded in December 2014, the company is rooted in over two decades of research by Dr. Soucek on Omomyc, recognized as the most effective direct Myc inhibitor. With cancer incidence surpassing 14 million cases annually and projected to rise significantly, conventional treatments often fail due to resistance. Peptomyc's approach seeks to inhibit Myc, which is deregulated in most human cancers and plays an essential role in tumor evolution. This strategic focus on Myc represents a promising avenue in cancer therapy, particularly for challenging cases such as lung, breast, and brain tumors, offering the potential to enhance patient survival rates where existing therapies may fall short.

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system aimed at the early detection of sepsis. The company focuses on rapidly identifying pathogens and providing antibiogram results within hours. Utilizing artificial intelligence, DeepUll's system not only detects the causative infectious agents but also assesses the patient's immunological and functional status, allowing for predictive insights into the potential onset and progression of sepsis. This capability enables healthcare professionals to deliver timely clinical responses, even before symptoms manifest, ultimately improving patient outcomes and reducing the unnecessary use of antimicrobials.

Ona Therapeutics, S.L. is a biotechnology company founded in 2019 and based in Barcelona, Spain. It specializes in the discovery and development of therapeutic biologics that specifically target tumor metastatic-initiating cells and lipid metabolism. As a spin-off from ICREA and the IRB Institute for Research in Biomedicine, the company focuses on blocking the pathways involved in fat metabolism in animal models of cancer. Its innovative therapies aim to inhibit the cells responsible for metastasis, thereby preventing the development of malignant tumors and potentially eradicating existing ones. Ona Therapeutics is positioned to offer treatment solutions for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Accure Therapeutics S.L. is a pharmaceutical company based in Barcelona, Spain, focused on the development, production, and marketing of drugs aimed at treating central nervous system (CNS) diseases. As a clinical-stage research and development entity, Accure Therapeutics specializes in creating disease-modifying therapies for both severe orphan and non-orphan CNS disorders. The company is committed to accelerating the transition to effective treatments for disabling brain conditions, thereby enabling healthcare professionals to better address the complexities of CNS-related illnesses.

Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

Mediktor is a developer of an advanced pre-diagnosis tool that utilizes artificial intelligence and natural language recognition to facilitate accurate symptom checking, triage, and decision-making support. The system is clinically validated and aims to transform healthcare by reducing access barriers for patients. It allows individuals to make informed decisions based on their initial symptoms while enabling healthcare providers to efficiently manage demand and optimize resources. Mediktor's technology connects patients with medical professionals within health insurance networks, assisting hospitals and health systems in making safe, rapid, and cost-effective healthcare decisions.

Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases.

Peptomyc is a biotechnology company dedicated to developing innovative therapeutics that utilize cell-penetrating peptides to target the Myc oncoprotein, a critical factor in cancer cell survival. Founded in December 2014, the company is rooted in over two decades of research by Dr. Soucek on Omomyc, recognized as the most effective direct Myc inhibitor. With cancer incidence surpassing 14 million cases annually and projected to rise significantly, conventional treatments often fail due to resistance. Peptomyc's approach seeks to inhibit Myc, which is deregulated in most human cancers and plays an essential role in tumor evolution. This strategic focus on Myc represents a promising avenue in cancer therapy, particularly for challenging cases such as lung, breast, and brain tumors, offering the potential to enhance patient survival rates where existing therapies may fall short.